Clopidogrel dosing and role of genetics: ELEVATE-TIMI 56 trial

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]

Overview

The results of the ELEVATE-TIMI 56 trial were recently presented in AHA 2011 held at Orlando, Florida.

[1]==ELEVATE-TIMI 56 trial ==

  • Hypothesis -
  • Study design
    • Patient population
      • Multicenter, randomized, double-blind trial
      • Duration of study - 1 years
      • Intervention -
      • Primary end point -
  • Limitations
  • Results -
  • Conclusions

References

  1. ↑ Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ; et al. (2011). "Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease". JAMA. 306 (20): 2221–8. doi:10.1001/jama.2011.1703. PMID 22088980.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Clopidogrel_dosing_and_role_of_genetics:_ELEVATE-TIMI_56_trial&oldid=613147"